Md. Safiullah Sarker

Dr. Md. Safiullah Sarker

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
SKSharful Islam Khan
Sharful Islam Khan
MRMasud Reza
Masud Reza
SCSuzanne M. Crowe
Suzanne M. Crowe
MRMustafizur Rahman
Mustafizur Rahman
MHMargaret Hellard
Margaret Hellard
Allen G. P. RossAllen G. P. Ross
Allen G. P. Ross
The rates of both HIV and HCV are exploding among the People Who Inject Drugs (PWID) subpopulation in the People's Republic of Bangladesh. 5,586 HIV confirmed cases have been reported since the first case of HIV was identified in 1989, of which, 865 new cases (15.5%) have been reported in the year 2017 alone. Among the new cases, 330 (38.2%) were from PWID population. The HCV prevalence is also high in Dhaka, with 40% of the PWID with unknown HIV status and 60.7% co-infected with HIV. The predominant HIV-1 strains circulating in the population are subtype C (41.4%) followed by CRF07 BC (24.2%), CRF01 AE (9.1), A1 (6.6%), and B (2.5%). HCV subtypes 3a and 3b are the most prevalent circulating strains (88.5%) among PWID. Harm reduction interventions particularly Needle Syringe Program (NSP) for PWID have been operating in Bangladesh since 1998. Opioid Substitution Therapy (OST) commenced in 2010 but only covers 2.9% of the total estimated PWID population in the country. A preliminary assessment of the needle/syringe sharing networks of HIV positive PWID was made in order to determine the HIV status among needle/syringe sharing partners. From a network of 36 HIV positive PWID seeds, 96 needle/syringe sharing partners were identified, of which 10 were HIV positive. Characterization of the nature of transmission within PWID networks is required in order to develop clinical services aimed at this vulnerable subpopulation and to halt the epidemic.

1 December 2019 in International Journal of Drug Policy
Verified
Journal Article
Closed access
MRMustafizur Rahman
Mustafizur Rahman
NJNaveed Zafar Janjua
Naveed Zafar Janjua
TSTanveer Khan Ibne Shafiq
Tanveer Khan Ibne Shafiq
ECEzazul Islam Chowdhury
Ezazul Islam Chowdhury
MSMd. Safiullah Sarker
Md. Safiullah Sarker
TATasnim Azim
Tasnim Azim

6 July 2025 in Cancer Control
Verified
Journal Article
Open access
MSMd. Safiullah Sarker
Md. Safiullah Sarker
Gynecological malignancies, including cervical, endometrial, and ovarian cancers, pose significant global health challenges due to their increasing incidence and limitations in conventional treatments. Current therapeutic approaches, such as surgery, chemotherapy, and radiation, often face obstacles like multidrug resistance, tumor recurrence, and adverse side effects. In response, emerging therapies—including targeted therapy, immunotherapy, and gene therapy—are reshaping treatment paradigms. Precision medicine, leveraging Poly ADP-ribose Polymerase (PARP) and Vascular Endothelial Growth Factor (VEGF) inhibitors, enhances therapeutic efficacy, while immune checkpoint inhibitors and vaccine-based therapies offer promising immunotherapeutic strategies. Additionally, advancements in nanotechnology and gene therapy, including Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) based approaches and nanoparticle-mediated drug delivery, provide novel treatment modalities. Despite these innovations, translational challenges persist, necessitating further research into clinical applications and personalized treatment strategies. This review highlights the latest advancements in emerging therapies for gynecological malignancies, emphasizing their potential to improve patient outcomes and address existing treatment limitations.

14 November 2023 in The Lancet Global Health
Verified
Journal Article
Open access
MSMd. Safiullah Sarker
Md. Safiullah Sarker

27 July 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MRMasud Reza
Masud Reza
GSGolam Sarwar
Golam Sarwar
SISamira Dishti Irfan
Samira Dishti Irfan
MKMohammad Niaz Morshed Khan
Mohammad Niaz Morshed Khan
ARA. K. M. Masud Rana
A. K. M. Masud Rana
SKSharful Islam Khan
Sharful Islam Khan
Background: Key populations (KPs) who are at risk of compromised situation of sexual and reproductive health and rights in Bangladesh constitute including males having sex with males, male sex workers, transgender women (locally known as hijra) and female sex workers. Globally, these key populations experience various sexual and reproductive health and rights burdens and unmet needs for ailments such as sexually transmitted infections including Neisseria Gonorrhoea, Chlamydia Trachomatis and human papillomavirus. Most key population focused interventions around the world, including Bangladesh, primarily address human immune deficiency virus and sexually transmitted infections-related concerns and provide syndromic management of sexually transmitted infections, other sexual and reproductive health and rights issues are remained overlooked that creates a lack of information in the related areas. There is currently no systematic research in Bangladesh that can produce representative data on sexual and reproductive health and rights among key populations, investigates their sexual and reproductive health and rights needs, how their needs evolve, and investigate underlying factors of sexual and reproductive health and rights issues that is crucial for informing more sexual and reproductive health and rights-friendly interventions for key populations. Keeping all these issues in mind, we are proposing to establish a sexual and reproductive health and rights surveillance system for key populations in Bangladesh. Method: The sexual and reproductive health and rights surveillance system will be established in Dhaka for males having sex with males, male sex workers and transgender women, and the other in Jashore for female sex workers. The duration will be for 3 years and data will be collected twice, in year one and year two adopting a mixed method repeated cross-sectional design. All key populations 15 years and above will be sampled. Behavioural data will be collected adopting a face-to-face technique and then biological samples will be collected. Those who will be found positive for human papillomavirus, will be referred to a government hospital for treatment. Free treatment will be provided to those who will be found positive for other sexually transmitted infections. In total, 2,240 key populations will be sampled. Written assent/consent will be taken from everyone. Data will be entered by Epi-Info and analysed by Stata. Report will be produced in every year. Discussion: This surveillance system will be the first of its kind to systematically assess the situation of sexual and reproductive health and rights among selected key populations in Bangladesh. It is expected that this study will provide insights needed for improving the existing sexual and reproductive health and rights intervention modalities for these vulnerable and marginalized key populations.

Verified
Journal Article
Open access
PDF file
MSMd. Safiullah Sarker
Md. Safiullah Sarker
RJRubiyat Jahan
Rubiyat Jahan
Genetic diversity and molecular epidemiology of HIV are directly relevant to HIV transmission. We report here the genetic diversity and transmission dynamics of non-C subtypes of HIV-1 strains detected in Bangladeshi key populations. Sequence analysis of gag gene revealed four subtypes A1, B, D, G, and nine CRFs (01_AE, 02_AG, 09_cpx, 10_CD, 15_AE/B, 13_cpx, 14_BG, 22_01_A1, and 25_AGU). Most of these non-C strains were detected in returnee migrant workers from different parts of the world. Phylogenetic analysis showed that the Bangladeshi HIV-1 strains detected in migrant workers and their wives and local sex workers shared common ancestries. The identification of the multiple subtypes indicates high diversity of non-C HIV-1 variants circulating in Bangladesh which might have been imported by migrant workers from multiple geographical areas.